Immunogenicity of hepatitis a vaccine in children with cancer.

Abstract

This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. Twenty-eight patients with lymphomas or solid tumors and who had negative serology for hepatitis A were enrolled. The median age was 4.7 years (range 2-16). The patients received 1440 IU hepatitis A vaccine at 0 and 6 months. Seroconversion rates at the first and seventh months were 60% (n = 17/28 patients) and 89% (n = 24/27 patients). No adverse effects were observed. The hepatitis A vaccine was found to be effective and safe in children with cancer.

• Authors: Yavuz Köksal, Bilgehan Yalçin, G Burça Aydin, Neriman Sari, Nalan Yazici, Ali Varan, Tezer Kutluk, Canan Akyüz, Münevver Büyükpamukçu
• Journal: Pediatric hematology and oncology (Pediatr Hematol Oncol) Vol. 23 Issue 8 Pg. 619-24 (Dec 2006) ISSN: 1521-0669 [Electronic] England
• PMID: 17065137 (Publication Type: Journal Article)

Chemical References

• Hepatitis A Antibodies
• Hepatitis A Vaccines
• Immunoglobulin G
• Immunoglobulin M

Topics

• Adolescent
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Hepatitis A Antibodies (biosynthesis, blood)
• Hepatitis A Vaccines (immunology)
• Humans
• Immunoglobulin G (biosynthesis, blood)
• Immunoglobulin M (biosynthesis, blood)
• Male
• Neoplasms (immunology)
• Prospective Studies